Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
FindCure Biosciences (ZhongShan) Co., Ltd.
Eastern Cooperative Oncology Group
Kaiser Permanente
University of Colorado, Denver
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
University of Nebraska
Adela, Inc
Eli Lilly and Company
Bayer
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
Instituto do Cancer do Estado de São Paulo
Columbia University
Theratechnologies
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
Universidade Federal de Pernambuco
Sotio Biotech Inc.
University of Modena and Reggio Emilia
VitaMed Research LLC
Salubris Biotherapeutics Inc
NantCell, Inc.
TransThera Sciences (Nanjing), Inc.
Beijing Friendship Hospital
Istituti Clinici Scientifici Maugeri SpA
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
University Medical Center Groningen
Hoffmann-La Roche
Stanford University
Kineta Inc.
Institut Bergonié
Blue Note Therapeutics
MacroGenics
Celgene
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)